Cargando…
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
BACKGROUND: Preoperative FOLFIRINOX chemotherapy is increasingly administered to patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) to improve overall survival (OS). Multicenter studies reporting on the impact from the number of preoperative cycles and the use o...
Ejemplares similares
-
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study
por: Lof, Sanne, et al.
Publicado: (2019) -
Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
por: Klompmaker, Sjors, et al.
Publicado: (2018) -
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
por: Frigerio, Isabella, et al.
Publicado: (2022) -
Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma
por: Malleo, Giuseppe, et al.
Publicado: (2021) -
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)